Redcare Pharmacy N.V. financials
Redcare Pharmacy N.V.
529900JK6UXHY1YKZ082 | Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Revenue | €2.94B | €2.37B |
| Cost of sales | €2.28B | €1.82B |
| Gross profit | €663.1M | €545.8M |
| Other income | €500.0K | €300.0K |
| Administrative expenses | €99.4M | €83.1M |
| Operating profit (EBIT) | -€28.5M | -€39.0M |
| Finance costs | €31.3M | €16.7M |
| Profit before tax | -€47.7M | -€47.9M |
| Income tax expense | -€8.3M | -€1.5M |
| Profit for the year | -€39.4M | -€46.4M |
| — attributable to owners | -€37.7M | -€45.5M |
| — attributable to NCI | -€1.7M | -€900.0K |
| Total comprehensive income | -€37.5M | -€46.1M |
| Per share | ||
| Basic EPS | €-1.87 | €-2.27 |
| Diluted EPS | €-1.87 | €-2.27 |
| Free cash flow / share | €-2.29 | €0.66 |
| Cash flow statement | ||
| Net cash from operating activities | €31.0M | €22.1M |
| Net cash from investing activities | -€146.6M | €8.4M |
| Purchase of PP&E (capex) | €79.3M | €8.7M |
| Purchase of intangibles | €39.3M | €33.4M |
| Net cash from financing activities | €111.3M | -€17.9M |
| Lease liability payments | €8.7M | €8.3M |
| Net change in cash | -€4.3M | €12.6M |
| Balance sheet | ||
| Total assets | €1.21B | €1.00B |
| Non-current assets | €594.9M | €503.3M |
| Property, plant & equipment | €119.9M | €49.8M |
| Right-of-use assets | €70.8M | €32.8M |
| Intangible assets & goodwill | €393.5M | €411.3M |
| Current assets | €619.4M | €500.0M |
| Inventories | €214.0M | €153.8M |
| Trade & other receivables | €129.5M | €109.8M |
| Cash & equivalents | €92.4M | €96.9M |
| Total equity | €479.2M | €510.0M |
| — attributable to owners | €459.2M | €484.0M |
| Non-controlling interests | €20.0M | €26.0M |
| Non-current liabilities | €335.1M | €243.6M |
| Current liabilities | €400.0M | €249.7M |
| Trade & other payables | €253.0M | €184.0M |
| Deferred tax liabilities | €4.4M | €3.6M |
| Derived metrics | ||
| Free cash flow | -€48.3M | €13.4M |
| Operating margin | -1.0% | -1.6% |
| Net margin | -1.3% | -2.0% |
| Return on equity | -8.2% | -9.1% |
| Cash conversion ratio | -0.79× | -0.48× |
| Capex coverage | 0.39× | 2.54× |
| Other reported items | ||
| Adjustments For Decrease Increase In Inventories | -€60.9M | -€17.4M |
| Adjustments For Decrease Increase In Trade and Other Receivables | -€18.9M | -€8.0M |
| Adjustments For Depreciation and Amortisation Expense | €75.9M | €68.2M |
| Adjustments For Increase Decrease In Trade and Other Payables | €68.5M | €25.1M |
| Adjustments For Sharebased Payments | €3.5M | €3.2M |
| Adjustments For Unrealised Foreign Exchange Losses Gains | €400.0K | €500.0K |
| Cash Flows From Used In Operations Before Changes In Working Capital | €50.7M | €32.3M |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | €0 | -€300.0K |
| Comprehensive Income Attributable To Noncontrolling Interests | -€800.0K | -€800.0K |
| Comprehensive Income Attributable To Owners of Parent | -€36.7M | -€45.3M |
| Current Accrued Expenses and Other Current Liabilities | €60.7M | €56.0M |
| Current Prepayments and Other Current Assets | €72.4M | €58.8M |
| Deferred Tax Assets | €1.6M | €1.4M |
| Deferred Tax Relating To Items Charged Or Credited Directly To Equity | -€9.5M | — |
| Dividends Paid To Noncontrolling Interests Classified As Financing Activities | €5.2M | €3.0M |
| Dividends Received From Associates Classified As Investing Activities | €300.0K | €100.0K |
| Dividends Recognised As Distributions To Noncontrolling Interests | €5.2M | €3.0M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -€200.0K | €100.0K |
| Equity and Liabilities | €1.21B | €1.00B |
| Finance Income | €11.7M | €7.4M |
| Gains Losses On Exchange Differences On Translation Before Tax | €0 | -€600.0K |
| Income Tax Relating To Remeasurements of Defined Benefit Plans of Other Comprehensive Income | €300.0K | €100.0K |
| Income Taxes Paid Refund Classified As Operating Activities | €600.0K | €600.0K |
| Increase Decrease In Working Capital | €19.7M | €10.2M |
| Increase Decrease Through Conversion of Convertible Instruments | -€19.5M | — |
| Increase Decrease Through Exercise of Options | €400.0K | €4.0M |
| Increase Decrease Through Sharebased Payment Transactions | €3.5M | €3.1M |
| Interest Paid Classified As Financing Activities | €12.8M | €9.0M |
| Interest Received Classified As Investing Activities | €4.5M | €6.8M |
| Investments In Joint Ventures Accounted For Using Equity Method | €1.5M | €1.4M |
| Issue of Convertible Instruments | €37.0M | — |
| Issue of Equity | €0 | €0 |
| Noncurrent Financial Liabilities | €330.3M | €237.6M |
| Noncurrent Provisions For Employee Benefits | €400.0K | €2.4M |
| Other Comprehensive Income | €1.9M | €300.0K |
| Other Comprehensive Income Before Tax Gains Losses On Remeasurements of Defined Benefit Plans | €2.2M | €1.0M |
| Other Current Financial Assets | €111.1M | €80.7M |
| Other Current Financial Liabilities | €86.3M | €9.7M |
| Other Noncurrent Financial Assets | €7.6M | €6.6M |
| Proceeds From Exercise of Options | €400.0K | €4.0M |
| Proceeds From Issue of Bonds Notes and Debentures | €296.3M | €0 |
| Proceeds From Sales Or Maturity of Financial Instruments Classified As Investing Activities | €0 | €40.0M |
| Repayments of Bonds Notes and Debentures | €157.3M | €0 |
| Repayments of Noncurrent Borrowings | €1.4M | €1.6M |
| Share of Profit Loss of Associates and Joint Ventures Accounted For Using Equity Method | €400.0K | €400.0K |
Every line item above is a fact tagged in Redcare Pharmacy N.V.'s annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.